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Children with sickle cell disease (SCD) incur greater medical expenditures than children without 38 
SCD. The prevalence of overweight has risen among children with SCD in recent years, but the 39 
impact of excess weight on both the disease burden and economic burden of SCD has not been 40 
determined. 41 
PROCEDURE: 42 
A convenience sample of patients with SCD under 18 years of age were asked to participate 43 
during a routine medical check-up. All participants were from one SCD clinic in North Carolina. 44 
Annual cost of care (CoC) in United States dollars (USD) was measured during four stages of 45 
adolescence (pre, early, middle, and late) for two groups of patients with SCD who were either 46 
above or below an age- and sex-specific 50th percentile for body mass index (BMI). 47 
RESULTS: 48 
A total of 33 African-American patients (mean age at enrollment 11.76 ± 3.13, 15 (45.5%) 49 
female) recorded 914 medical encounters spanning 306 patient-years. For patients over the 50th 50 
BMI percentile, CoC was estimated to increase by an additional $1,006 (𝑝 < 0.001) per year. 51 
The estimated difference in annual CoC became most pronounced in late adolescence, wherein 52 
patients in the higher percentile group incurred an additional annual CoC of $11,695 (𝑝 =53 
0.019). 54 
CONCLUSIONS: 55 
The differences we measured in cost of care for patients with SCD gives weight to the hypothesis 56 
that economic burden is exacerbated by excess bodyweight. Differences in the domain of 57 
healthcare costs also suggest potential benefits of weight-management interventions. Further 58 
studies implementing such interventions may provide insights for strategically managing SCD, 59 
reducing economic burden and improving patient outcomes. 60 
 61 
1 INTRODUCTION 62 
Sickle cell disease (SCD), a family of inherited autosomal recessive genetic disorders, affects 63 
approximately 1 in 500 African Americans and 100,000 individuals in the US.1 Increasing life 64 
expectancy for patients with SCD2 has facilitated the study of health-related quality of life3 65 
(HRQOL) and cost of care4 (CoC). Children with SCD utilize healthcare more frequently5,6 and 66 
incur greater CoC than peers without SCD.7–9 Recent evidence suggests that overweight and 67 
obesity are becoming more prevalent among children and adults with SCD in both the developed 68 
and developing worlds,10–13 but there is limited understanding regarding the economic impact of 69 
these health risk factors. 70 
Obesity is associated with greater CoC amongst children in the US14,15 and other developed 71 
nations.16–19 Several factors influence the impact of obesity on CoC, including gender20 and 72 
socioeconomic status.19 With increasing rates of overweight and obesity among persons with 73 
SCD, there has been speculation regarding an association between excess weight and increased 74 
CoC,11,13,21 and the current body of literature is in need of longitudinal studies to measure the 75 
impact of sustaining excess weight during adolescence for patients with SCD. 76 
In this article, we summarize a retrospective cohort study that extracted medical encounter data 77 
from electronic medical records (EMR) for consecutive pediatric and adolescent patients with 78 
SCD. We statistically estimate and compare (1) the rate of change in annual CoC for patients 79 
with high and low standardized body mass index (BMI) values (𝑍 scores) and (2) the expected 80 
annual CoC during four stages of adolescence, controlling for sex, insurance type, year, age at 81 
enrollment, and socioeconomic status. Our results make a case for further study of the 82 
association between overweight and increased medical and economic burden for patients with 83 
SCD in a more controlled setting involving one or more nutrition and exercise based 84 
interventions. 85 
 86 
2 METHODS 87 
2.1 Recruitment 88 
As part of a larger study on the adolescent transition period for adolescents with chronic medical 89 
conditions, a convenience sample of patients with SCD under 18 years of age was recruited from 90 
one comprehensive sickle cell clinic. Details of the longitudinal sample and study design and 91 
inclusion and exclusion criteria have been previously published.22 This current study’s inclusion 92 
criteria included a confirmed diagnosis of SCD, ability to speak and understand English, and 93 
freedom of cognitive impairment (determined by health care provider) that would inhibit ability 94 
to complete study activities. After institutional review board approval, patients with SCD and 95 
their parents were invited to participate and informed consents were obtained from study 96 
participants and their parents. 97 
2.2 Data Collection 98 
Data were collected from the EMR at University of North Carolina Pediatric Sickle Cell Clinic. 99 
All participants' medical records were reviewed and anthropometric, financial, and demographic 100 
data were extracted from WebCIS, a Legacy record, (2004-2014) and EPIC (2014-2016) systems 101 
at each outpatient, inpatient, or emergency room visit. 102 
2.3 Measures 103 
The measurement of time is paramount in longitudinal studies, so we present results based on 104 
two perspectives of patient age. More specifically, age was considered as both a continuous and 105 
categorical variable. For the latter, we split numeric age values into a total of four stages of 106 
adolescence based on guidelines set by the American Academy of Pediatrics23: pre-adolescence 107 
(age 8 to 11), early adolescence (age 11 to 15), middle adolescence (age 15 to 18), and late 108 
adolescence (age 18 to 21). Regarding age as a continuous variable, we used the numeric values 109 
of 9.5, 13, 16.5, and 19.5 years in place of the group identifiers. Annual CoC in United States 110 
dollars (USD) for each stage was constructed by summing CoC at the encounter level for each 111 
patient within each stage and dividing by the spanning number of years. For example, if a 112 
patient’s total CoC from age 8 to 11 was 99 dollars, their annual CoC would be 99 / (11-8) = 33 113 
dollars per year. 114 
Some patients' data either began or ended near the borders of a stage (e.g., collection began at 115 
age 10.8 or ended at age 18.1). Allowing these borderline encounters to represent CoC for an 116 
entire stage leads to underestimation of the true CoC, yet overestimation results from pushing the 117 
borderline values into the closest stage (i.e. using the initial encounter at age 10.8 as an 118 
observation in the early adolescence stage). For these reasons we elected to exclude borderline 119 
encounters, which were defined as encounters that occurred during a patient’s final or initial 120 
stage but did not cover more than half of the stage's duration. Figure 1 illustrates our inclusion 121 
and exclusion process for a fictional set of encounters from one patient as well as the formulation 122 
of three annual CoC values. The fictional patient's initial encounter is a borderline case and is 123 
excluded. Since the spanning time between the onset of the late adolescence stage and the final 124 
encounter is greater than 75% of the stage duration, the final encounter is included. 125 
 126 
FIGURE 1 Data inclusion and exclusion process. NOTE: The cost values in the figure are 127 
fictional. 128 
 129 
Standardized BMI values, often referred to as standard deviation or 𝑍 scores, were used to 130 
measure the weight status of patients throughout the study. The 𝑍 scores were formed by 131 
mapping BMI values into sex- and age-specific BMI percentiles that were based on reference 132 
data compiled by the Center for Disease Control and Prevention (CDC).24 The documentation of 133 
the y2z function in the AGD package25 describes how these values were mapped in full detail. 134 
We split the sample into two exposure groups by setting observations with 𝑍 scores above or 135 
below zero as the upper or lower weight group, respectively. We did not compare overweight to 136 
non-overweight patients, which would require splitting along the 85th percentile (𝑍 = 1.1). 137 
Instead, we use the 50th percentile (1) to preserve statistical power and (2) because patients with 138 
SCD have historically maintained lower BMIs relative to their peers without SCD.26 With 139 
regards to reason (2), a 'normal BMI' SCD patient according to standard growth charts may in 140 
fact be in the upper BMI percentiles of the SCD population. 141 
Additional variables included patient's median neighborhood income (based on patient zip code), 142 
medical insurance type (private or public), sex (male or female), year at the onset of an age 143 
period (e.g., 2009 when patient was 15, 2012 when patient was 18), and age at enrollment. 144 
2.4 Statistical Analyses 145 
All statistical analyses were produced with R version 3.3.0.27 Descriptive statistics (e.g. 146 
groupwise mean values and standard errors) were considered prior to application of the 147 
generalized linear model (GLM)28 with generalized estimating equations (GEE)29,30 and a log 148 
link function.31 This technique is a generalization of analysis of variance with unequal sample 149 
sizes and clustered outcomes that do not maintain a bell shaped distribution.32 Tests of difference 150 
between two means33 using the GLM with GEE generalizes the paired t-test by using all 151 
observations from each participant (even if the participant had only one value) and also adjusting 152 
for the correlation between observations within subjects. For these comparisons, we fixed each 153 
of the continuous control variables (income and age at enrollment) upon their respective sample 154 
means. 155 
2.5 Missing Data 156 
Missing data at the encounter level included 121 (13%) height values and 67 (7%) weight values. 157 
We imputed these missing values using a weighted mean of previous and future values based 158 
upon temporal proximity. Height values for patients over the age of 18 were carried forward for 159 
all subsequent observations. 160 
Missing data at the subject level included 6 (6%) income values. We assumed these data were 161 
missing completely at random (MCAR) and conducted sensitivity analyses by separately 162 
constructing a model using the complete cases (excluding subjects with missing values) data and 163 
another using the full data (including imputed values). The complete cases model was in full 164 
agreement with inferences made by the full data model, indicating that the MCAR assumption 165 
was valid. After establishing the MCAR assumption, we applied multiple imputation using the 166 
conditional specification implemented by the MICE algorithm34 to impute the missing income 167 
values. 168 
 169 
3 RESULTS 170 
3.1 Enrollment of Participants 171 
A total of 33 patients recorded 914 medical encounters spanning 306 patient-years. After 172 
collapsing the encounter level data to form the annual outcomes within age periods, we had a 173 
total of 99 observations. Removing observations based on borderline encounters left a total of 96 174 
observations. 175 
3.2 Sample Characteristics 176 
Mean age at entry and final encounter were 11.76 ± 3.13 and 18.74 ± 1.88 years, respectively. 177 
The sample had a total of 15 (45.5%) female participants and 18 (54.5%) males. Most 178 
participants (17 (51.5%)) were in the lower 𝑍 score group, and the mean 𝑍 score was -0.14 ± 179 
1.09. All participants were identified by parents or guardians as African American and 32 (97%) 180 
were not of Hispanic ethnicity. The mean reported income plus or minus one standard deviation 181 
(SD) was $49,150.55 ± 13,787.84. Last, 22 (66.7%) patients were primarily insured with a type 182 
of public insurance (e.g. Medicaid) and 11 (33.3%) patients with a type of private insurance. 183 
Table 1 summarizes the sample characteristics for each 𝑍 score group. 184 
 185 
TABLE 1 Sample Characteristics.  186 
 
Lower BMI 
n = 17 (51.5) 
Higher BMI 
n = 16 (48.5) 
All 
n = 33 
Number of observations (p = 0.253) 3.1 ± 0.8 2.8 ± 0.7 2.9 ± 0.8 
Age (years) at enrollment (p = 0.678) 12.0 ± 3.0 11.5 ± 3.4 11.8 ± 3.1 
Age (years) at conclusion (p = 0.047) 19.4 ± 1.2 18.1 ± 2.3 18.7 ± 1.9 
Income (USD) (p = 0.366) 47,008 ± 12,998 51,427 ± 14,650 49,151 ± 13,788 
Z Value (p < 0.001) -0.9 ± 1.0 0.7 ± 0.4 -0.1 ± 1.1 
Sex (p = 0.024)    
   Female 4 (23.5) 11 (68.8) 15 (45.5) 
   Male 13 (76.5) 5 (31.2) 18 (54.5) 
Billing Party (p = 0.538)    
   Public 10 (58.8) 12 (75.0) 22 (66.7) 
   Private 7 (41.2) 4 (25.0) 11 (33.3) 
For continuous variables, values are mean ± standard deviation.  
For categorical variables, values are frequency (%). 
BMI: body mass index; USD: United States dollar 
 187 
Figure 2 displays subject-specific annual CoC values (small grey points) for upper and lower 188 
BMI 𝑍 score groups across the four age periods. Mean annual CoC values are displayed as larger 189 
black points with error bars showing the width of one standard deviation above and below the 190 
mean. Observation counts and mean values plus or minus one standard deviation are also 191 
tabulated at the bottom of the figure. 192 
 193 
FIGURE 2 Unadjusted mean annual CoC (USD) ± SD  194 
 195 
3.3 Difference in Slopes 196 
The rate of change per year in annual CoC was estimated from the GLM with a continuous age 197 
predictor. For the low 𝑍 score group, the estimated change in annual CoC from age 8 to 21 was 198 
$42 (95% CI: -71 to 155). For the high 𝑍 score group, the estimated slope was $1,047 (95% CI: 199 
488 to 1,607). To summarize, CoC was estimated to increase by an additional $1,006 (95% CI: 200 
445 to 1,566) per year for high 𝑍 score patients. 201 
3.4 Difference in Means 202 
Using the categorical formulation of age, Table 2 presents estimated least-squares (LS) means 203 
and standard errors (SE) of annual CoC as well as estimated differences between annual CoC 204 
between 𝑍 score groups for each age period. Difference values are computed by subtracting the 205 
estimated mean of the lower 𝑍 score group from that of the higher 𝑍 score group. In the two 206 
earliest age periods (pre- and early adolescence), we estimated modest difference in CoC 207 
between groups. During middle adolescence we measured a nontrivial difference of $2,231 (95% 208 
CI: -1,768 to 6,230) that did not achieve statistical significance. A substantial and statistically 209 
significant (𝑝 = 0.019) difference of $11,695 (95% CI: 1,759 to 21,632) was measured during 210 
late adolescence. 211 
 212 
TABLE 2 Comparison of estimated cost of care means 213 
 
Age Group 












Pre 1,308 (598) 6 959 (403) 9 -349 0.488 
Early 2,260 (862) 15 2,361 (1146) 12 101 0.926 
Middle 2,877 (895) 16 5,108 (2338) 15 2,231 0.264 
Late 1,659 (510) 13 13,354 (4953) 10 1,1695 0.019 
Means presented in United States dollars 
LS: least-squares; SE: standard error 
 214 
4 DISCUSSION 215 
This retrospective cohort study aimed to estimate the rate of change in annual CoC for patients 216 
with high and low standardized BMI values and the expected annual CoC during four stages of 217 
adolescence. For higher 𝑍 score patients, CoC was estimated to increase by an additional $1,006 218 
(𝑝 < 0.001) per year. The estimated difference in annual CoC became most pronounced in late 219 
adolescence, wherein patients with higher 𝑍 scores incurred an additional annual CoC of $11,695 220 
(𝑝 = 0.019). 221 
We experienced a number of challenges in the course of this study that may prove relevant for 222 
future studies. Data collection through EMR proved to be very accurate for cost data, but less so 223 
for data concerning age, weight, height, and other patient information relating to demographic 224 
and socioeconomic factors. Improving the accuracy and consistency of information kept in 225 
electronic medical records could potentially alleviate many of the limitations we experienced and 226 
allow more studies such as this to be conducted. One of the primary limitations of this research 227 
(in addition to a small number of patients) is that data were collected within a single hospital 228 
system and patients may have visited multiple hospitals over their adolescence. Pooling patient 229 
data from multiple institutions in future studies could alleviate this limitation. 230 
These data suggest that at some point in adolescence, the CoC of patients with SCD becomes 231 
highest in overweight patients and this trend carries forward into adulthood. One of the main 232 
virtues of observational data is their capacity to generate relevant hypotheses for future research. 233 
Previous research has associated overweight status with increases in the burden of SCD,11 and 234 
this has motivated exploration of how these patterns emerge over time. Based on these premises 235 
we have summarized several points in this article to present evidence of association between 236 
overweight and increased CoC for patients with SCD beginning in the late teen years. Our 237 
findings should not be interpreted as causal association but should motivate exploration of data-238 
driven hypotheses.  239 
A recent study4 estimated that the annual CoC for patients with SCD in the United States 240 
exceeded one billion dollars. The authors also commented that a small proportion of patients 241 
with SCD accounted for a large proportion of healthcare expenditures, which we have also found 242 
to be the case in our sample. If excess weight plays a role in the development of severe 243 
symptoms that in turn account for a large proportion of the total CoC for SCD, then there may be 244 
both clinical and economic benefits to healthcare providers informing patients about the likely 245 
consequences of the disease for different weight groups. Future research could address whether 246 
there is potential to reduce the medical cost of SCD in young adults with weight management 247 
interventions. 248 
The relationship between excess weight and increased CoC may be supported by previous 249 
literature. Overweight status is associated with comorbidities that may be of particular 250 
significance for disease management and CoC in the SCD population. Recently, high BMI was 251 
found to be associated with hypertension and increased risk of stroke within an adult population 252 
with SS genotype.35 Excess weight has also been associated with increased pain interference in 253 
daily activities among adults with SCD.11 Children with SCD experience much higher rates of 254 
snoring and sleep apnea, associated in the general population with overweight status, than the 255 
general population36 and it has been shown that lower nocturnal hemoglobin saturations appear 256 
to be associated with increased vaso-occlusive pain crises.21 There is also strong evidence that 257 
snoring and sleep apnea are associated with increased cerebral, cognitive, and behavioral 258 
morbidity.36 However, studies conflict on the presence of a direct relationship between weight 259 
status and sleep apnea or hypertension in children with SCD.13,36 It could then be hypothesized 260 
that excess weight, through various mechanisms (e.g., metabolic syndrome, hypertension, and 261 
hypoxic sleep disturbances), has negative consequences for morbidity and CoC. 262 
Current SCD care guidelines from the National Heart, Lung, and Blood Institute only 263 
superficially address weight management,37 and we believe amendment of these guidelines to 264 
reflect the main points of this study and others35 would be an important step towards higher 265 
quality healthcare and lower CoC for patients with SCD. Although we have mainly focused on 266 
the implications of excess weight in patients with SCD, the relationship between growth failure, 267 
delayed puberty, and underweight status in many patients with SCD26,38–41 should also be 268 
considered in potential amendments. 269 
Another implication of these findings is for the financing of SCD care. Two thirds of this study’s 270 
participants utilized public insurance, consistent with literature suggesting the majority of 271 
patients with SCD in the US rely on Medicaid.42–44 If cost-effective weight management 272 
interventions can be validated for the SCD population, stakeholders such as the Centers for 273 
Medicare and Medicaid Services and other insurance and healthcare providers may be 274 
encouraged to invest further in health promotion efforts for patients with SCD. 275 
 276 
5 CONCLUSION 277 
Sickle cell disease affects around 100,000 individuals in the US and amounts to over a billion 278 
dollars of healthcare expenditures per year. Recent evidence suggests that the prevalence of 279 
overweight and obesity status for these individuals is growing. The relationship between obesity 280 
and rising healthcare costs has been studied thoroughly, but the nature of this relationship within 281 
the SCD population remains unexplored. In this study, we analyzed longitudinal EMR data to 282 
assess the association between standardized BMI values (𝑍 scores) and CoC for patients with 283 
SCD. For higher 𝑍 score patients, CoC was estimated to increase by an additional $1,006 (𝑝 <284 
0.001) per year. The estimated difference in annual CoC became most pronounced in late 285 
adolescence, wherein patients with higher 𝑍 scores incurred an additional annual CoC of $11,695 286 
(𝑝 = 0.019). These observational data have provided evidence that gives weight to the 287 
hypothesis that preventative therapy of SCD-related health complications via weight 288 
management interventions may substantially reduce the economic burden of SCD for pediatric 289 
patients. 290 
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